Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Graft Versus Host Disease (GVHD): Likelihood of Approval
Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease...
Data Insights
Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Systemic Lupus Erythematosus: Likelihood of Approval
Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Systemic Lupus Erythematosus. According...